Brokerages Set Perspective Therapeutics, Inc. (NYSE:CATX) PT at $15.14

Perspective Therapeutics, Inc. (NYSE:CATX) has been given an average rating of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $15.14.

Several research analysts recently weighed in on CATX shares. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Oppenheimer cut their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Monday, January 13th.

Insider Activity

In other news, CEO Johan M. Spoor purchased 8,000 shares of Perspective Therapeutics stock in a transaction dated Wednesday, December 4th. The stock was acquired at an average cost of $3.77 per share, for a total transaction of $30,160.00. Following the acquisition, the chief executive officer now directly owns 36,257 shares in the company, valued at $136,688.89. This represents a 28.31 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Jonathan Robert Hunt acquired 12,829 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the acquisition, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. The trade was a 35.66 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 67,570 shares of company stock worth $256,789 in the last ninety days. Corporate insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. nVerses Capital LLC bought a new stake in Perspective Therapeutics during the third quarter worth approximately $57,000. Trueblood Wealth Management LLC boosted its holdings in shares of Perspective Therapeutics by 37.0% during the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company’s stock worth $71,000 after buying an additional 6,000 shares during the period. SG Americas Securities LLC grew its stake in Perspective Therapeutics by 41.3% in the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company’s stock valued at $83,000 after buying an additional 7,627 shares during the last quarter. US Bancorp DE raised its holdings in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after acquiring an additional 3,866 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in Perspective Therapeutics during the 2nd quarter worth $117,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $3.52 on Friday. Perspective Therapeutics has a 52-week low of $2.70 and a 52-week high of $19.05. The firm has a 50-day moving average price of $4.14 and a two-hundred day moving average price of $9.94.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Sell-side analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.